Benefits and limitations of reducing glucagon action for the treatment of type 2 diabetes

被引：90

作者：

Ali, Safina ^{[1
]}

Drucker, Daniel J. ^{[1
]}

机构：

[1] Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Dept Med, Toronto, ON M5T 3L9, Canada

来源：

AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM | 2009年 / 296卷 / 03期

关键词：

RECEPTOR KNOCKOUT MICE; DEPENDENT INSULINOTROPIC PEPTIDE; HEPATIC GLUCOSE OUTPUT; DIET-INDUCED OBESITY; POSTPRANDIAL HYPERGLYCEMIA; PHYSIOLOGICAL LEVELS; ENDOGENOUS GLUCAGON; GLYCEMIC CONTROL; BETA-CELLS; DAIRY-COWS;

D O I：

10.1152/ajpendo.90887.2008

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Ali S, Drucker DJ. Benefits and limitations of reducing glucagon action for the treatment of type 2 diabetes. Am J Physiol Endocrinol Metab 296: E415-E421, 2009. First published December 30, 2008; doi:10.1152/ajpendo.90887.2008.-Glucagon is secreted from the alpha-cells of the pancreatic islets and regulates glucose homeostasis through modulation of hepatic glucose production. As elevated glucagon levels contribute to the pathophysiology of hyperglycemia in subjects with type 2 diabetes, reduction of glucagon receptor gene (Gcgr) activity represents a potential target for the treatment of T2DM. Herein, we review current concepts of glucagon action in hepatic and extrahepatic tissues and evaluate the therapeutic potential, mechanisms of action, and safety of reducing Gcgr signaling for the treatment of T2DM.

引用

页码：E415 / E421

页数：7

共 76 条

[1] CENTRAL GLUCAGON-INDUCED HYPERGLYCEMIA IS MEDIATED BY COMBINED ACTIVATION OF THE ADRENAL-MEDULLA AND SYMPATHETIC-NERVE ENDINGS [J].

AMIR, S .

PHYSIOLOGY & BEHAVIOR, 1986, 37 (04) :563-566

[2] Glucagon suppression of ghrelin secretion is exerted at hypothalamus-pituitary level [J].

Arafat, A. M. ;

Perschel, F. H. ;

Otto, B. ;

Weickert, M. O. ;

Rochlitz, H. ;

Schoefl, C. ;

Spranger, J. ;

Moehlig, M. ;

Pfeiffer, A. F. H. .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2006, 91 (09) :3528-3533

[3] Biology of incretins: GLP-1 and GIP [J].

Baggio, Laurie L. ;

Drucker, Daniel J. .

GASTROENTEROLOGY, 2007, 132 (06) :2131-2157

[4] Extracellular cAMP inhibits proximal reabsorption: are plasma membrane cAMP receptors involved? [J].

Bankir, L ;

Ahloulay, M ;

Devreotes, PN ;

Parent, CA .

AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY, 2002, 282 (03) :F376-F392

[5] Insulin as a physiological modulator of glucagon secretion [J].

Bansal, Pritpal ;

Wang, Qinghua .

AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM, 2008, 295 (04) :E751-E761

[6] ROLE OF HYPERGLUCAGONEMIA IN MAINTENANCE OF INCREASED RATES OF HEPATIC GLUCOSE OUTPUT IN TYPE-II DIABETICS [J].

BARON, AD ;

SCHAEFFER, L ;

SHRAGG, P ;

KOLTERMAN, OG .

DIABETES, 1987, 36 (03) :274-283

[7] Effects of type 2 diabetes on the regulation of hepatic glucose metabolism [J].

Basu, A ;

Shah, P ;

Nielsen, M ;

Basu, R ;

Rizza, RA .

JOURNAL OF INVESTIGATIVE MEDICINE, 2004, 52 (06) :366-374

[8] Effects of exogenous glucagon on lipids in lipoproteins and liver of lactating dairy cows [J].

Bobe, G ;

Ametaj, BN ;

Young, JW ;

Beitz, DC .

JOURNAL OF DAIRY SCIENCE, 2003, 86 (09) :2895-2903

[9] Evidence for a major role for glucagon in regulation of plasma glucose in conscious, nondiabetic, and alloxan-induced diabetic rabbits [J].

Brand, CL ;

Jorgensen, PN ;

Svendsen, I ;

Holst, JJ .

DIABETES, 1996, 45 (08) :1076-1083

[10] IMMUNONEUTRALIZATION OF ENDOGENOUS GLUCAGON WITH MONOCLONAL GLUCAGON ANTIBODY NORMALIZES HYPERGLYCEMIA IN MODERATELY STREPTOZOTOCIN-DIABETIC RATS [J].

BRAND, CL ;

ROLIN, B ;

JORGENSEN, PN ;

SVENDSEN, I ;

KRISTENSEN, JS ;

HOLST, JJ .

DIABETOLOGIA, 1994, 37 (10) :985-993

← 1 2 3 4 5 6 7 8 →